These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

593 related articles for article (PubMed ID: 27718298)

  • 21. Proteomics analysis reveals novel components in the detergent-insoluble subproteome in Alzheimer's disease.
    Gozal YM; Duong DM; Gearing M; Cheng D; Hanfelt JJ; Funderburk C; Peng J; Lah JJ; Levey AI
    J Proteome Res; 2009 Nov; 8(11):5069-79. PubMed ID: 19746990
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amyloid-beta and phosphorylated tau in post-mortem Alzheimer's disease retinas.
    den Haan J; Morrema THJ; Verbraak FD; de Boer JF; Scheltens P; Rozemuller AJ; Bergen AAB; Bouwman FH; Hoozemans JJ
    Acta Neuropathol Commun; 2018 Dec; 6(1):147. PubMed ID: 30593285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dogs with Cognitive Dysfunction as a Spontaneous Model for Early Alzheimer's Disease: A Translational Study of Neuropathological and Inflammatory Markers.
    Schütt T; Helboe L; Pedersen LØ; Waldemar G; Berendt M; Pedersen JT
    J Alzheimers Dis; 2016 Mar; 52(2):433-49. PubMed ID: 27003213
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oxidative balance in Alzheimer's disease: relationship to APOE, Braak tangle stage, and the concentrations of soluble and insoluble amyloid-β.
    Tayler H; Fraser T; Miners JS; Kehoe PG; Love S
    J Alzheimers Dis; 2010; 22(4):1363-73. PubMed ID: 20930272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating small extracellular vesicles in Alzheimer's disease: a case-control study of neuro-inflammation and synaptic dysfunction.
    Singh R; Rai S; Bharti PS; Zehra S; Gorai PK; Modi GP; Rani N; Dev K; Inampudi KK; Y VV; Chatterjee P; Nikolajeff F; Kumar S
    BMC Med; 2024 Jun; 22(1):254. PubMed ID: 38902659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduction of amyloid beta by Aβ3-10-KLH vaccine also decreases tau pathology in 3×Tg-AD mice.
    Zhang HY; Zhu K; Meng Y; Ding L; Wang JC; Yin WC; Yan Y; Cao YP
    Brain Res Bull; 2018 Sep; 142():233-240. PubMed ID: 30077729
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distinct relationships of amyloid-beta and tau deposition to cerebral glucose metabolic networks in Alzheimer's disease.
    Sun X; Nie B; Zhao S; Ai L; Chen Q; Zhang T; Pan T; Wang L; Yin X; Zhang W; Shan B; Liu H; Liang S; Wang G
    Neurosci Lett; 2020 Jan; 717():134699. PubMed ID: 31874218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differences in the cerebral amyloid angiopathy proteome in Alzheimer's disease and mild cognitive impairment.
    Leitner D; Kavanagh T; Kanshin E; Balcomb K; Pires G; Thierry M; Suazo JI; Schneider J; Ueberheide B; Drummond E; Wisniewski T
    Acta Neuropathol; 2024 Jul; 148(1):9. PubMed ID: 39039355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Testing a MultiTEP-based combination vaccine to reduce Aβ and tau pathology in Tau22/5xFAD bigenic mice.
    Davtyan H; Hovakimyan A; Kiani Shabestari S; Antonyan T; Coburn MA; Zagorski K; Chailyan G; Petrushina I; Svystun O; Danhash E; Petrovsky N; Cribbs DH; Agadjanyan MG; Blurton-Jones M; Ghochikyan A
    Alzheimers Res Ther; 2019 Dec; 11(1):107. PubMed ID: 31847886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice.
    Rhein V; Song X; Wiesner A; Ittner LM; Baysang G; Meier F; Ozmen L; Bluethmann H; Dröse S; Brandt U; Savaskan E; Czech C; Götz J; Eckert A
    Proc Natl Acad Sci U S A; 2009 Nov; 106(47):20057-62. PubMed ID: 19897719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heparin-enriched plasma proteome is significantly altered in Alzheimer's disease.
    Guo Q; Ping L; Dammer EB; Duong DM; Yin L; Xu K; Shantaraman A; Fox EJ; Golde TE; Johnson ECB; Roberts BR; Lah JJ; Levey AI; Seyfried NT
    Mol Neurodegener; 2024 Oct; 19(1):67. PubMed ID: 39380021
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice.
    Oddo S; Caccamo A; Cheng D; Jouleh B; Torp R; LaFerla FM
    J Neurochem; 2007 Aug; 102(4):1053-63. PubMed ID: 17472708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concomitant LATE-NC in Alzheimer's disease is not associated with increased tau or amyloid-β pathological burden.
    McAleese KE; Walker L; Erskine D; Johnson M; Koss D; Thomas AJ; Attems J
    Neuropathol Appl Neurobiol; 2020 Dec; 46(7):722-734. PubMed ID: 32896913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Expression of apolipoprotein E in Alzheimer's disease and its significance].
    He SR; Liu DG; Wang S; Xia YJ
    Zhonghua Bing Li Xue Za Zhi; 2005 Sep; 34(9):556-60. PubMed ID: 16468304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline.
    Clausen A; Xu X; Bi X; Baudry M
    J Alzheimers Dis; 2012; 30(1):183-208. PubMed ID: 22406441
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cognitive Decline in Preclinical Alzheimer's Disease: Amyloid-Beta versus Tauopathy.
    Huber CM; Yee C; May T; Dhanala A; Mitchell CS
    J Alzheimers Dis; 2018; 61(1):265-281. PubMed ID: 29154274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protein aggregation in Alzheimer's disease: Aβ and τ and their potential roles in the pathogenesis of AD.
    Thal DR; Fändrich M
    Acta Neuropathol; 2015 Feb; 129(2):163-5. PubMed ID: 25600324
    [No Abstract]   [Full Text] [Related]  

  • 39. Remote Associations Between Tau and Cortical Amyloid-β Are Stage-Dependent.
    Hojjati SH; Chiang GC; Butler TA; de Leon M; Gupta A; Li Y; Sabuncu MR; Feiz F; Nayak S; Shteingart J; Ozoria S; Gholipour Picha S; Stern Y; Luchsinger JA; Devanand DP; Razlighi QR
    J Alzheimers Dis; 2024; 98(4):1467-1482. PubMed ID: 38552116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human tau increases amyloid β plaque size but not amyloid β-mediated synapse loss in a novel mouse model of Alzheimer's disease.
    Jackson RJ; Rudinskiy N; Herrmann AG; Croft S; Kim JM; Petrova V; Ramos-Rodriguez JJ; Pitstick R; Wegmann S; Garcia-Alloza M; Carlson GA; Hyman BT; Spires-Jones TL
    Eur J Neurosci; 2016 Dec; 44(12):3056-3066. PubMed ID: 27748574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.